Covestor Ltd Increases Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Covestor Ltd lifted its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 107.4% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 618 shares of the specialty pharmaceutical company’s stock after buying an additional 320 shares during the period. Covestor Ltd’s holdings in Jazz Pharmaceuticals were worth $74,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Kovack Advisors Inc. boosted its position in shares of Jazz Pharmaceuticals by 88.8% during the first quarter. Kovack Advisors Inc. now owns 56,599 shares of the specialty pharmaceutical company’s stock valued at $6,816,000 after purchasing an additional 26,628 shares in the last quarter. Baupost Group LLC MA boosted its position in shares of Jazz Pharmaceuticals by 23.7% during the fourth quarter. Baupost Group LLC MA now owns 833,696 shares of the specialty pharmaceutical company’s stock valued at $102,545,000 after purchasing an additional 160,000 shares in the last quarter. Polaris Capital Management LLC boosted its position in shares of Jazz Pharmaceuticals by 2.2% during the fourth quarter. Polaris Capital Management LLC now owns 1,267,460 shares of the specialty pharmaceutical company’s stock valued at $155,898,000 after purchasing an additional 27,100 shares in the last quarter. John G Ullman & Associates Inc. bought a new stake in shares of Jazz Pharmaceuticals during the first quarter valued at approximately $3,631,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of Jazz Pharmaceuticals during the fourth quarter valued at approximately $380,000. 89.14% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Jazz Pharmaceuticals

In other news, EVP Neena M. Patil sold 5,000 shares of the company’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $109.65, for a total value of $548,250.00. Following the completion of the transaction, the executive vice president now owns 36,629 shares of the company’s stock, valued at $4,016,369.85. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 4.20% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Morgan Stanley dropped their target price on Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating on the stock in a report on Friday, July 12th. Barclays dropped their target price on Jazz Pharmaceuticals from $230.00 to $200.00 and set an “overweight” rating on the stock in a report on Friday, May 3rd. Cantor Fitzgerald reissued an “overweight” rating and issued a $180.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, April 10th. Needham & Company LLC dropped their target price on Jazz Pharmaceuticals from $222.00 to $210.00 and set a “buy” rating on the stock in a report on Thursday, June 20th. Finally, HC Wainwright reissued a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Friday, May 3rd. Three equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $185.86.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $108.78 on Thursday. The company has a quick ratio of 1.90, a current ratio of 2.27 and a debt-to-equity ratio of 1.38. The business has a 50-day simple moving average of $107.18 and a two-hundred day simple moving average of $114.52. The stock has a market cap of $6.86 billion, a price-to-earnings ratio of 22.43, a PEG ratio of 1.67 and a beta of 0.58. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $146.70.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 EPS for the quarter, missing analysts’ consensus estimates of $3.53 by ($1.55). The company had revenue of $901.98 million during the quarter, compared to analysts’ expectations of $938.99 million. Jazz Pharmaceuticals had a return on equity of 27.86% and a net margin of 8.61%. On average, analysts expect that Jazz Pharmaceuticals plc will post 15.32 EPS for the current year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.